LOS ANGELES, July 25, 2011 /PRNewswire/ -- Genesis Biopharma,
Inc. (OTC.BB:GNBP), a biotechnology company developing targeted
cancer therapies, and Lonza (SIX: LONN), today announced the
signing of a process development and scale-up agreement relating to
the manufacture of Contego™, Genesis Biopharma's autologous cell
therapy product candidate for the treatment of Stage IV metastatic
melanoma.
Contego™ is a ready-to-infuse cell therapy based on currently
available therapies at the National Cancer Institute, MD Anderson
Cancer Center, and the H. Lee Moffitt Cancer & Research
Institute. "We are pleased to have such an experienced
bioprocess development and manufacturing partner as Lonza," stated
Mr. Anthony J. Cataldo, Chairman and
Chief Executive Officer of Genesis Biopharma.
"Lonza is pleased to be in partnership with Genesis Biopharma,
and to bring expertise in large-scale autologous cell therapy
production to the task of making Contego™ widely available to
patients suffering from metastatic melanoma," said David Smith, Head of Therapeutic Cell Solutions
at Lonza.
About Genesis Biopharma, Inc.
Genesis Biopharma, Inc. is a development-stage biotechnology
company engaged in the development of targeted cancer therapies.
For more information about the company, visit
www.genesis-biopharma.com.
About Lonza
Lonza is one of the world's leading suppliers to the
pharmaceutical, healthcare and life science industries. Products
and services span its customers' needs from research to final
product manufacture. It is the global leader in the production and
support of active pharmaceutical ingredients both chemically as
well as biotechnologically. Biopharmaceuticals are one of the key
growth drivers of the pharmaceutical and biotechnology industries.
Lonza has strong capabilities in large and small molecules,
peptides, amino acids and niche bioproducts which play an important
role in the development of novel medicines and healthcare products.
In addition, Lonza is a leader in cell-based research, endotoxin
detection and cell therapy manufacturing. Furthermore, the company
is a leading provider of value chemical and biotech ingredients to
the nutrition, hygiene, preservation, agro and personal care
markets.
Lonza is headquartered in Basel,
Switzerland and is listed on the SIX Swiss Exchange. In
2010, the company had sales of CHF 2.680
billion. Further information can be found at
www.lonza.com.
SOURCE Genesis Biopharma, Inc.
